PUBBLICATO IL NUOVO NUMERO DELLA WHO PHARMACEUTICAL NEWSLETTER

Fonte: WHO. N 5, ottobre 2017

E' disponibile il nuovo numero della WHO Pharmaceutical newsletter.

In questo numero:

REGULATORY MATTERS
• Atypical antipsychotics
• Azithromycin
• Combined use of buprenorphine or methadone with benzodiazepines or CNS depressants
• Dabigatran
• Doxycycline
• Gadolinium based contrast agents for MRI
• Hyoscine butylbromide ampoule
• Ibrutinib
• Laninamivir
• Methylprednisolone injections containing lactose
• Palivizumab
• Paracetamol (modified- or prolonged-release)
• Riociguat
• Selexipag
• Sodium polystyrene sulfonate
• Trimebutine based medicines
• Warfarin

SAFETY OF MEDICINE
• Brivudine
• Corticosteroids
• Desloratadine
• Direct-acting antivirals (DAAs)
• Fluindione
• Iron isomaltoside
• Ketamine.
• Lithium
• Obeticholic acid
• Pembrolizumab
• Prasugrel
• Teriflunomide

SIGNAL
• Amitriptyline and dry eyes – an ADR overlooked in labelling
Insufficiently labelled ADRs: abdominal pain, chest pain and headache while using noscapine
• Complete loss of libido reported for women on systemic hormonal contraceptive

FEATURE
• APEC Harmonization Center (AHC) Pharmacovigilance Workshop, Seoul, 11-12 September 2017
• The second workshop to integrate Anatomical Therapeutic Chemical (ATC) and Defined Daily Dose (DDD) in drug utilization research